Reactive　oxygen　species　(ROS)-based　nanodynamic　therapy　is　emerging　as　a　promising　approach　for　tumor　treatment,　particularly　in　eliciting　immune　responses　for　tumor　immunotherapy.　Nevertheless,　the　complex　tumor　microenvironment　(TME)　and　the　constraints　of　current　sensitizers　substantially　compromise　therapeutic　efficacy.　To　address　these　challenges,　we　developed　a　rationally　designed　nanoplatform　(LP/CuTT)　through　lipoic　acid-modified　orchestrated　Cu-2(+)-coordinated　tetracycline-porphyrin　self-assembly,　to　precisely　remodel　the　immunosuppressive　TME　while　potentiating　antitumor　immunotherapy　via　a　novel　photo-enhanced　chemodynamic　therapy　(CDT)　strategy.　In　vitro　studies　demonstrated　that　LP/CuTT-mediated　photo-enhanced　CDT　effectively　promoted　concurrent　apoptosis　and　cuproptosis　in　B16-F10　melanoma　cells,　coupled　with　robust　induction　of　immunogenic　cell　death　(ICD).　Mechanistic　investigations　revealed　that　LP/CuTT　drives　macrophage　polarization　from　tumor-promoting　M2　to　antitumor　M1　phenotypes　while　promoting　dendritic　cell　(DC)　maturation,　thereby　orchestrating　potent　antitumor　immune　responses.　In　vivo　evaluations　showed　preferential　tumor　accumulation　of　LP/CuTT,　correlating　with　substantial　ROS　generation　at　tumor　sites　and　remarkable　therapeutic　outcomes.　Quantitative　assessments　further　demonstrated　elevated　M1　macrophage　infiltration　in　both　tumor　and　splenic　tissues,　accompanied　by　enhanced　CD8(+)　and　CD4(+)　T　cell　recruitment.　These　findings　provide　key　insights　into　developing　orchestrated　metal-coordinated　nanotherapeutics　by　repurposing　existing　therapeutic　agents,　enabling　the　design　of　multifunctional　systems　that　integrate　efficient　chemodynamic　activity,　TME　remodeling,　and　immune　activation　for　effective　nanodynamic　therapy.